Blazing saddles! Bicycle wheels out changes at the top
Travis Thompson, Michael Method and Mike Skynner all take on key new roles in the reshuffle by the Nasdaq-quoted business, which has its global HQ at Granta Park.
Thompson, who began at Bicycle in April 2018 and most recently served as senior vice president and chief accounting officer, becomes chief financial officer. He previously spent his career at EY in its life sciences practice supporting a broad range of companies of all sizes and stages of development.
As CFO, he will continue to oversee finance and accounting functions and now also investor relations. Alethia Young, who has stepped down as CFO, will remain with Bicycle in an interim capacity for three months and then continue as a company adviser.
Michael Method, who started at Bicycle in June 2025 and most recently served as senior vice president, clinical development, has been promoted to chief medical officer (CMO), overseeing all clinical development and the relationship with Bicycle’s Clinical Advisory Board.
Dr. Method is an academic and clinical oncologist with extensive drug development experience at many oncology companies, including ImmunoGen and Eli Lilly. Eric Westin, who has retired from his role as CMO, will continue with Bicycle as a distinguished fellow.
Skynner, who began at Bicycle in January 2016 and most recently served as chief technology officer, becomes chief scientific officer. Dr. Skynner will oversee scientific discovery, early-stage pipeline development and the relationship with Bicycle’s Research and Innovation Advisory Board.
CEO Kevin Lee says: “Bicycle made significant progress in 2025 and looks forward to achieving its 2026 priorities. We believe our evolved leadership team, in collaboration with our expert board of directors and advisers, positions us to build momentum across our innovative pipeline and create shareholder value.
“On behalf of our board of directors and team, I want to thank Alethia and Eric for helping the company obtain a strong financial position and advance our clinical trials. As we look to the future, we are excited to progress our targeted oncology clinical programs that include our new radiopharmaceutical strategic partnerships.
“With strengthened operational capacity and financial runway expected into 2028, I am pleased to have Travis, Michael and Michael step into their new roles after successful tenures at Bicycle. Together, with the rest of our leadership team, talented employees and board of directors, we believe we can realise our goal to help patients live longer and live well.”
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics.
Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilise their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development.
